U.S. Markets closed

Synageva Phase 3 ARISE trial met primary endpoint

Synageva BioPharma announced that the global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial of sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency met the primary endpoint of normalization of alanine aminotransferase, ALT, a marker of liver injury. In addition, sebelipase alfa significantly improved multiple other disease-related abnormalities as measured by a number of secondary endpoints.